Related Experiment Video

Updated: Jun 9, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Poly (ADP-ribose) polymerase as a novel therapeutic target in cancer

Christina M Annunziata1, Joyce O'Shaughnessy

  • 1Medical Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|September 9, 2010
PubMed

Insights

Cancer chemotherapy targets DNA repair defects. Poly (ADP-ribose) polymerase (PARP) inhibitors show promise for synthetic lethality in BRCA-deficient cancers, highlighting a new therapeutic strategy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Cancer chemotherapy leverages DNA damage repair deficiencies in malignant cells.
  • Specific DNA repair pathway defects in cancers influence sensitivity and resistance to cytotoxic agents.
  • BRCA proteins and Poly (ADP-ribose) polymerase (PARP) are crucial for DNA strand break repair.

Purpose of the Study:

  • To explore the role of DNA repair defects in cancer treatment sensitivity.
  • To investigate the potential of Poly (ADP-ribose) polymerase (PARP) inhibitors in BRCA-deficient tumors.
  • To identify sporadic cancers susceptible to DNA-damaging agents.

Main Methods:

  • Review of recent clinical trials involving Poly (ADP-ribose) polymerase (PARP) inhibitors.
  • Analysis of the relationship between BRCA deficiency and sensitivity to DNA-damaging agents.
  • Examination of genomic instability in sporadic cancers.

Main Results:

  • BRCA-deficient cancers, including breast and ovarian cancers, exhibit sensitivity to DNA-damaging agents and Poly (ADP-ribose) polymerase (PARP) inhibitors.
  • Clinical trials indicate Poly (ADP-ribose) polymerase (PARP) inhibitors can induce synthetic lethality in BRCA-pathway-deficient tumors.
  • Defective DNA repair pathways contribute to mutation accumulation and cancer development.

Conclusions:

  • Poly (ADP-ribose) polymerase (PARP) inhibitors represent a promising therapeutic strategy for BRCA-deficient cancers.
  • Targeting DNA repair pathways offers a novel approach to cancer chemotherapy.
  • Further research is needed to identify sporadic cancers with genomic instability for targeted therapies.

More Related Videos

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog08:37

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

Published on: November 5, 2014

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...